

IFW

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents P.O. Box 1450, Alexandria, VA 22313-1450 on:



2/14/05
Date of Deposit

Our File No. LOU02-016-US

Paul E. Rauch, Ph.D.
Name

[Signature]
Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | |
|---|---|-------------------------|
| In re Application of: |) | |
| Cedric Francois |) | |
| Serial No. 10/724,527 |) | |
| Filing Date: November 28, 2003 |) | Examiner Gyan Chandra |
| For Compositions and Methods for Treating Transplants |) | Group Art Unit No. 1646 |

TRANSMITTAL

M.S. - Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


Transmitted herewith is:

- ☒ Response to Restriction Requirement
- ☒ No additional fee is required.
- ☒ The Commissioner is hereby authorized to charge any fees associated with this communication not covered by check or credit card payment or credit any overpayment to Deposit Account No. 50-3123. A duplicate copy of this sheet is attached.

Respectfully submitted,

[Signature]
Paul E. Rauch, Ph.D.
Registration No. 38,591

Evan Law Group LLC
566 West Adams
Suite 350
Chicago, Illinois 60661
(312) 876-1400




I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class in an envelope addressed to: Commissioner for Patents
P.O. Box 1450, Alexandria, VA 22313-1450 on:

14 February 2005
Date of Deposit

Our File No. LOU02-016-US

Paul E. Rauch, Ph.D.

Name


Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | |
|--------------------------------|---|-------------------------|
| In re Application of: |) | |
| |) | |
| Cedric Francois |) | |
| |) | |
| Serial No. 10/724,527 |) | Examiner Gyan Chandra |
| |) | |
| Filing Date: November 28, 2003 |) | Group Art Unit No. 1646 |
| |) | |
| For COMPOSITIONS AND METHODS |) | |
| FOR TREATING TRANSPLANTS |) | |

RESTRICTION RESPONSE

M.S. - Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Action of January 12, 2005, Applicant elects Group III, with traverse, claims 20-23. Furthermore, as a single disclosed species of phospholipids, applicant elects (i) DOPC, which is 1,2-dioleoyl-sn-glycero-3-phosphocholine; and as a single disclosed species of polar lipid, applicant elects (iii) formula XVIII. Claims 20-23 (as well as claims 24-30) read on the elected species, and all these claims are generic.

Applicant also requests that the examiner reconsider the grouping of the claims, and include claims 24-26, since they include all the limitations of claim 20, as well as claims 27-31, as they all depend from claim 20.